Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › Cervarix

Cervarix

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of Cervarix

18 trials tracked of Cervarix: 13 in phase 3 or 4 and 2 with published results. The most-cited published study has 49 citations.

18Trials tracked
13Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 1 Phase 3 12 Phase 2 3 Phase 1 1 Other / NA 1
  1. Phase 3 Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females Completed · 49 cited
  2. Phase 3 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults Completed · 12 cited
  3. Phase 4 Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents Completed
  4. Phase 3 Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation. Completed
  5. Phase 3 Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects Completed
  6. Phase 3 Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old Completed
Show 12 more trials
  1. Phase 3 Safety Study of GSK Biologicals' HPV Vaccine (GSK-580299) in Healthy Female Subjects. Completed
  2. Phase 3 Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18 Completed
  3. Phase 3 Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18 Completed
  4. Phase 3 Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women Completed
  5. Phase 3 Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects Completed
  6. Phase 3 Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age. Completed
  7. Phase 3 Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older Completed
  8. Phase 2 Follow-up Study to Evaluate the Long-term Efficacy of the HPV Vaccine (580299) in Healthy Young Adult Women in Brazil Completed
  9. Phase 2 Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in HIV Infected Females Completed
  10. Phase 2 Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North America Completed
  11. Phase 1 Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs Completed
  12. N/A Evaluation of Safety of a Vaccine Against Cervical Cancer in Healthy Korean Females Completed

Showing the 18 most-cited and recently-updated of 18 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Malaria presence at vaccination reduces HPV16 and HPV18 antibody levels in two-dose arms
Pediatrics RCT
Malaria presence at vaccination reduces HPV16 and HPV18 antibody levels in two-dose arms Malaria Presence Linked to Lower HPV Vaccine Antibody Levels
This randomized controlled trial of 930 HIV-negative Tanzanian schoolgirls found that malaria presence at vaccination was associated with lo…
A study in Tanzania found that malaria may lower certain antibody responses in girls receiving two doses of the HPV vaccine.
Aug 30, 2026